Prostate Cancer: Early Stage

Hear from Our Patients

Dan's Story

“I was determined to educate myself about all of my options, and thanks to Oncotype DX, I have not lost any sleep or been worried since I received my Oncotype DX Genomic Prostate Score.”

Dan W., a 60-year-old husband, grandfather, and attorney, was diagnosed with prostate cancer in September 2013, and was presented with the choice of surgery or radiation treatment.  Alarmed by the likely side effects of incontinence and impotence, Dan began his own research and became intrigued with a third option – active surveillance, or regular and close monitoring of his disease. When his physician questioned this possibility, Dan continued to search for answers – a quest that led him to learn about the new Oncotype DX prostate cancer test.

Dan then met with a radiation oncologist who was willing to recommend the new test based on his positive experience with the Oncotype DX breast cancer test. When Dan’s Oncotype DX Genomic Prostate Score (GPS) result came back, it placed him in the “very low risk” group.  As a result, Dan and his wife, Debbie, were confident about choosing active surveillance.  According to Dan, “I was determined to educate myself about all of my options, and thanks to Oncotype DX, I have not lost any sleep or been worried since I received my GPS result.

Read More

Jim's Story

“My doctor came to me and said, “We would like to do a genomic test, and we already have the tissue from the biopsy.”…To have all of the knowledge that I have about the disease, about my particular type of cancer. It's giving me the opportunity to do a lot of the things that I would like to do in life.”

Jim G., had been experiencing rises in his PSA and decided to get a prostate biopsy. The biopsy confirmed Gleason 6 prostate cancer, and Jim began to consider his treatment options. Since it was a low-risk prostate cancer, Jim’s urologist recommended Oncotype to first better understand the aggressiveness of the cancer. Jim was quite relieved when he received a GPS Score of 10, and knowing his cancer was not aggressive, Jim decided to go on active surveillance. “It would be premature to do any aggressive treatment at this point. It’s just not time. Maybe in the future, but not now.” Jim hopes to encourage all men to learn about their cancer and understand all their options before making a treatment decision. Jim is an avid golfer and photographer and enjoys spending time with his wife, children and grandkids.

Read More

News Coverage

A recent Wall Street Journal article features men who've used the Oncotype DX Genomic Prostate Score test to choose active surveillance.

Read the Article

Your Prostate. Your Decision.


With a Genomic Prostate Score of 10, Jim chose active surveillance.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™